BHIC — BioScience Health Innovations Income Statement
0.000.00%
Last trade - 00:00- $46.35m
- $45.66m
- $5.69m
Annual income statement for BioScience Health Innovations, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 August 31st | 2022 November 30th | 2022 August 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 3 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-Q | 10-K | 10-K | 10-K |
| Standards: | USG | — | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 1.84 | 5.69 |
| Cost of Revenue | |||||
| Gross Profit | — | — | — | 1.31 | 3.24 |
| Selling / General / Administrative Expenses | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 0.026 | 0.029 | 0.083 | 1.76 | 4.97 |
| Operating Profit | -0.026 | -0.029 | -0.083 | 0.087 | 0.719 |
| Net Income Before Taxes | -0.026 | -0.029 | -0.083 | 0.087 | 0.719 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -0.026 | -0.029 | -0.083 | 0.087 | 0.642 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -0.026 | -0.029 | -0.083 | 0.087 | 0.642 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -0.026 | -0.029 | -0.083 | 0.087 | 0.642 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.019 | -0.021 | -0.067 | 0.008 | 0.056 |
| Dividends per Share |